| Cell line name |
HCI-EC-23 |
| Synonyms |
Huntsman Cancer Institute-Endometrial cancer-23 |
| Accession |
CVCL_E3GB |
| Resource Identification Initiative |
To cite this cell line use: HCI-EC-23 (RRID:CVCL_E3GB) |
| Comments |
Characteristics: Retains ER expression and hormonal responsiveness (PubMed=36396974). Characteristics: Established from a mouse xenograft (EC-PDX-23) (PubMed=36396974). Doubling time: ~30 hours (PubMed=36396974). Microsatellite instability: Instable (MSI-high) (PubMed=36396974). Omics: Genomics; ChIP-seq; H3K27ac. Omics: Genomics; Whole exome sequencing. Omics: Transcriptomics; RNAseq. Derived from site: In situ; Endometrium; UBERON=UBERON_0001295. |
| Sequence variations |
- Mutation; HGNC; HGNC:11110; ARID1A; Simple; p.Gly801Valfs*32 (c.2402delG); Zygosity=Unspecified (PubMed=36396974).
- Mutation; HGNC; HGNC:11110; ARID1A; Simple; p.Gln2070Ter (c.6208C>T); Zygosity=Unspecified (PubMed=36396974).
- Mutation; HGNC; HGNC:15840; KMT2B; Simple; p.Gly1733Trpfs*6 (c.5196dupT); Zygosity=Unspecified (PubMed=36396974).
- Mutation; HGNC; HGNC:7133; KMT2D; Simple; p.Ser4327Glnfs*7 (c.12978dupG); Zygosity=Unspecified (PubMed=36396974).
- Mutation; HGNC; HGNC:14234; NSD1; Simple; p.Met1531Cysfs*43 (c.4591delA); Zygosity=Unspecified (PubMed=36396974).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu39Lys (c.115G>A); ClinVar=VCV003258061; Zygosity=Unspecified (PubMed=36396974).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Arg93Gln (c.278G>A); ClinVar=VCV000419128; Zygosity=Unspecified (PubMed=36396974).
- Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Arg130Gly (c.388C>G); ClinVar=VCV000375958; Zygosity=Unspecified (PubMed=36396974).
- Mutation; HGNC; HGNC:777; ZFHX3; Simple; p.Arg2693Ter (c.8077C>T); ClinVar=VCV004292719; Zygosity=Unspecified (PubMed=36396974).
|
| Disease |
Type I endometrial adenocarcinoma (NCIt: C40145) |
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
| Sex of cell |
Female |
| Age at sampling |
66Y |
| Category |
Cancer cell line |
| STR profile |
Source(s): ABM=T8158; Millipore=SCC641
Markers:| Amelogenin | X |
| CSF1PO | 12,13 |
| D3S1358 | 16,17 |
| D5S818 | 11 |
| D7S820 | 10,11 |
| D8S1179 | 12,13,14 |
| D13S317 | 11,12 |
| D16S539 | 11,12 |
| D18S51 | 12,15 |
| D21S11 | 28,29 |
| FGA | 20,24,25 |
| Penta D | 11,12 |
| Penta E | 12,15 |
| TH01 | 9.3,10 |
| TPOX | 8,9 |
| vWA | 17,19,20 |
Run an STR similarity search on this cell line |
| Publications | PubMed=36396974; DOI=10.1038/s41598-022-24211-8; PMCID=PMC9672046 Craig M. Rush, Zannel Blanchard, Jacob T. Polaski, Kyle S. Osborne, Krystle Osby, Jeffery M. Vahrenkamp, Chieh-Hsiang Yang, David H. Lum, Christy R. Hagan, Kimberly K. Leslie, Miles A. Pufall ...Show all 13 authors... , Kristina W. Thiel, Jason Gertz; Show fewer authors Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line. Sci. Rep. 12:19731.1-19731.17(2022) |
| Cross-references |
| Cell line collections (Providers) |
ABM; T8158
Millipore; SCC641
|
| Gene expression databases |
GEO; GSM6421755
GEO; GSM6421756
GEO; GSM6421757
GEO; GSM6421761
GEO; GSM6421762
GEO; GSM6421763
GEO; GSM6421764
GEO; GSM6421765
GEO; GSM6421766
GEO; GSM6421767
GEO; GSM6421768
GEO; GSM6727284
GEO; GSM6727285
|
| Entry history |
| Entry creation | 19-Dec-2024 |
| Last entry update | 27-Nov-2025 |
| Version number | 4 |
|---|